Potential coverage of a multivalent M protein-based group A streptococcal vaccine

Vaccine

Volumn 31, Issue 12, 2013, Pages 1576-1581

  Dale, James B ^a   Penfound, Thomas A ^a   Tamboura, Boubou ^b   Sow, Samba O ^b,c   Nataro, James P ^c,d   Tapia, Milagritos ^c   Kotloff, Karen L ^c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b Centre pour le Developpment des Vaccins (CVD Mali)   (Mali)

^c University of Maryland School of Medicine Center for Vaccine Development   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Bactericidal activity; Group A streptococcal vaccine; M protein; Vaccine coverage

Indexed keywords

ANTIBODIES,ANTISERA AND IMMUNOGLOBULINS; M PROTEIN; STREPTOCOCCUS VACCINE;

ADOLESCENT; ANIMAL EXPERIMENT; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CHILD; GROUP A STREPTOCOCCAL INFECTION; HIGH RISK POPULATION; HUMAN; NONHUMAN; PHARYNGITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RABBIT; RHEUMATIC HEART DISEASE; SCHOOL CHILD; SEROTYPE;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CARRIER PROTEINS; CHILD; HUMANS; MALI; PHARYNGITIS; RABBITS; SEROTYPING; SERUM BACTERICIDAL TEST; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES;

EID: 84875271992     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.01.019     Document Type: Article

References (24)

1. Carapetis J.R., Steer A.C., Mulholland E.K., Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005, 5(11):685-694.
2. Marijon E., Ou P., Celermajer D.S., Ferreira B., Mocumbi A.O., Jani D., et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med 2007, 357(5):470-476.
3. Paar J.A., Berrios N.M., Rose J.D., Caceres M., Pena R., Perez W., et al. Prevalence of rheumatic heart disease in children and young adults in Nicaragua. Am J Card 2010, 105(12):1809-1814.
4. Beaton A., Okello E., Lwabi P., Mondo C., McCarter R., Sable C. Echocardiography screening for rheumatic heart disease in Ugandan school children. Circulation 2012, 125(25):3127-3132.
5. Jackson S.J., Steer A.C., Campbell H. Systematic review: estimation of global burden of non-suppurative sequelae of upper respiratory tract infection: rheumatic fever and post-streptococcal glomerulonephritis. Trop Med Int Health 2011, 16(1):2-11.
6. Steer A.C., Law I., Matatolu L., Beall B.W., Carapetis J.R. Global emm-type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis 2009, 9(10):611-616.
7. Dale J.B. Current status of group A streptococcal vaccine development. Adv Exp Med Biol 2008, 609:53-63.
8. Hu M., Walls M., Stroop S., Reddish M., Beall B., Dale J. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 2002, 70:2171-2177.
9. McNeil S.A., Halperin S.A., Langley J.M., Smith B., Warren A., Sharratt G.P., et al. Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005, 41(8):1114-1122.
10. Dale J.B., Penfound T.A., Chiang E.Y., Walton W.J. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine 2011, 29(46):8175-8178.
11. Lancefield R.C. Current knowledge of the type specific M antigens of group A streptococci. J Immunol 1962, 89:307-313.
12. Lancefield R.C. Persistence of type-specific antibodies in man following infection with group A streptococci. J Exp Med 1959, 110:271-292.
13. Wannamaker L.W. The epidemiology of streptococcal infection 1954, Columbia University Press, New York.
14. Shulman S.T., Tanz R.R., Kabat W., Kabat K., Cederlund E., Patel D., et al. Group A streptococcal pharyngitis serotype surveillance in North America, 2000-2002. Clin Infect Dis 2004, 39(3):325-332.
15. Shulman S.T., Tanz R.R., Dale J.B., Beall B., Kabat W., Kabat K., et al. Seven-year surveillance of North American pediatric group a streptococcal pharyngitis isolates. Clin Infect Dis 2009, 49(1):78-84.
16. O'Loughlin R.E., Roberson A., Cieslak P.R., Lynfield R., Gershman K., Craig A., et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis 2007, 45(7):853-862.
17. Luca-Harari B., Darenberg J., Neal S., Siljander T., Strakova L., Tanna A., et al. Clinical and microbiological characteristics of severe streptococcus pyogenes disease in Europe. J Clin Microbiol 2009, 47(4):1155-1165.
18. Tapia M, Sow SO, Tamboura B, Nataro JP, Penfound TA, Dale JB, et al. Molecular epidemiology of streptococcal pharyngitis in Bamako, Mali; unpublished results.
19. Beall B., Facklam R., Thompson T. Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol 1996, 34(4):953-958.
20. Lancefield R.C. Differentiation of group A streptococci with a common R antigen into three serologic types with special reference to the bactericidal test. J Exp Med 1957, 106:525-544.
21. Swiss Institute of Bioinformatics SIM Alignment Program. Available from: [cited 23.8.2012]. http://web.expasy.org/sim.
22. CDC Streptococcal Reference Page [cited August 23, 2012]. Available from: . ftp://ftp.cdc.gov/pub/infectious_diseases/biotech/tstransl/.
23. Penfound T., Chiang E., Ahmed E., Dale J. Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes. Vaccine 2010, 28(31):5017-5022.
24. Dale JB, Fischetti VA, Carapetis JR, Steer AC, Sow SO, Kumar R, et al. Group A streptococcal vaccines: paving a path for accelerated development. Vaccine; in press.